LivFul develops STAYTEC™, a proprietary technology for next-generation repellents, to enhance access to effective mosquito protection in underserved communities. The company addresses the systemic issue of health access by providing affordable and reliable healthcare solutions that improve quality of life for millions.
Funding
$24.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many underserved communities lack access to effective and affordable mosquito repellents, leading to increased risk of mosquito-borne diseases like malaria, Zika virus, and dengue fever. Existing repellent solutions are often inaccessible, unaffordable, or ineffective in these regions, perpetuating health disparities.
Solution
LivFul develops and distributes STAYTEC™, a proprietary repellent technology designed to provide enhanced and affordable mosquito protection. STAYTEC™ aims to address the systemic issue of health access by offering reliable healthcare solutions that improve the quality of life in vulnerable populations. The company focuses on creating accessible and impactful products through innovative business models and supply chain solutions.
Target Audience
The primary target audience includes individuals and communities in regions with high mosquito-borne disease prevalence, particularly those with limited access to existing repellent solutions.
Features
- STAYTEC™ technology for next-generation mosquito repellents
- Akiva®: LivFul's anti-mosquito lotion utilizing STAYTEC™
- Focus on affordability and accessibility for underserved communities
- End-to-end execution from innovation to impact
- Supply chain innovations for cost-effective distribution